Literature DB >> 9151790

T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.

Y W Tang1, B S Graham.   

Abstract

Manipulation of the cytokine microenvironment at the time of vaccination can influence immune responses to remote challenge, providing a strategy to study the molecular pathogenesis of respiratory syncytial virus (RSV) vaccine-enhanced disease in the mouse model. Although treatment with antibody against IL-4 or recombinant IL-12 (rIL-12) at the time of formalin-inactivated RSV vaccination induced a similar shift in the pattern of cytokine mRNA expression upon live virus challenge, anti-IL-4 treated mice had increased CD8+ cytotoxic T lymphocyte activity and reduced illness compared with rIL-12-treated mice. To define effector mechanisms responsible for these patterns, CD4+ and/or CD8+ T lymphocytes were selectively depleted in vivo at the time of RSV challenge. In rIL-12-treated mice, CD4+ lymphocytes made the largest contribution to IFN-gamma mRNA, RSV clearance, and illness, while in anti-IL-4 treated mice, CD8+ lymphocytes were the major effector. The effector responsible for virus clearance also mediated illness, suggesting that efficiency of virus clearance determined disease expression. These results demonstrate that the phenotype of effector cells involved in the immune response to virus challenge may be a more important determinant of disease than patterns of cytokine expression classically assigned to Th1 and Th2 lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151790      PMCID: PMC508048          DOI: 10.1172/JCI119391

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

1.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Authors:  L C Afonso; T M Scharton; L Q Vieira; M Wysocka; G Trinchieri; P Scott
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

2.  Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.

Authors:  A Cesano; S Visonneau; S C Clark; D Santoli
Journal:  J Immunol       Date:  1993-09-15       Impact factor: 5.422

Review 3.  Adjuvants: current status, clinical perspectives and future prospects.

Authors:  F M Audibert; L D Lise
Journal:  Immunol Today       Date:  1993-06

4.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Authors:  D P Dialynas; Z S Quan; K A Wall; A Pierres; J Quintáns; M R Loken; M Pierres; F W Fitch
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

5.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

6.  Different roles of alpha beta and gamma delta T cells in immunity against an intracellular bacterial pathogen.

Authors:  P Mombaerts; J Arnoldi; F Russ; S Tonegawa; S H Kaufmann
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

7.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  Effects of IL-12 on the response and susceptibility to experimental viral infections.

Authors:  J S Orange; S F Wolf; C A Biron
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

9.  Distinct types of lung disease caused by functional subsets of antiviral T cells.

Authors:  W H Alwan; W J Kozlowska; P J Openshaw
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  Induction of murine peritoneal gamma/delta T cells and their role in resistance to bacterial infection.

Authors:  M J Skeen; H K Ziegler
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  19 in total

1.  Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; John D Nicewonger; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

3.  Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection.

Authors:  K K Tekkanat; H Maassab; A A Berlin; P M Lincoln; H L Evanoff; M H Kaplan; N W Lukacs
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.

Authors:  T R Johnson; B S Graham
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Michael N Teng; Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

8.  Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Steven M Varga; Thomas J Braciale; Barney S Graham
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 9.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

10.  Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.

Authors:  Teresa R Johnson; Marc E Rothenberg; Barney S Graham
Journal:  J Leukoc Biol       Date:  2008-06-02       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.